MetaCap

Insmed (INSM) vs Takeda Pharmaceutical (TAK)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Takeda Pharmaceutical (TAK) has outperformed Insmed (INSM) over the past year, gaining 52.2% versus a loss of 28.9%. Over five years, INSM leads with a +388.5% price change compared with +60.9% for TAK. Takeda Pharmaceutical is the larger company by market cap ($69.55 billion vs $31.01 billion), about 2.2 times the size.

On valuation, Takeda Pharmaceutical trades at a lower forward P/E (41.1x vs 220.2x for Insmed). Takeda Pharmaceutical pays a dividend yielding 927.88%, while Insmed does not currently pay one.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

INSM-28.89%TAK+52.24%
+58%-1%-59%
Nov 21, 20251 yearNov 20, 2026
INSM+363.99%TAK+55.39%
+614%+268%-77%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

INSM versus TAK key metrics
MetricINSMTAK
Share price$141.33$21.77
Market cap$31.01B$69.55B
1-day change-2.17%+1.68%
YTD return-18.79%+39.64%
1-year return-28.89%+52.24%
5-year return+388.52%+60.90%
P/E ratio (TTM)—311.00
Forward P/E220.1841.08
EPS (TTM)$-2.81$0.07
Dividend yield0.00%927.88%
Annual dividend$0.00$202.00
Revenue (latest FY)$606.42M—
Revenue growth (YoY)+66.73%—
Net income (latest FY)$-1.28B—
Gross margin79.73%—
Operating margin-205.59%—
Net margin-210.54%—
52-week high$212.75$22.07
52-week low$90.39$14.16
Distance from 52-week high-33.57%-1.36%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+37.39%+12.68%
Average volume3.09M2.73M
Shares outstanding219.38M3.19B
Employees1,66447,029
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Takeda Pharmaceutical is about 2.2 times larger than Insmed by market value ($69.55B vs $31.01B).
  • TAK has outperformed INSM by 81.1 percentage points over the past year.
  • Takeda Pharmaceutical offers a meaningfully higher dividend yield (927.88% vs 0.00%).

About Insmed

INSM stock →

Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients.

Health Care · Biotechnology: Pharmaceutical Preparations · 1,664 employees

About Takeda Pharmaceutical

TAK stock →

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience.

Health Care · Biotechnology: Pharmaceutical Preparations · 47,029 employees

INSM vs TAK FAQ

Which is bigger, Insmed or Takeda Pharmaceutical?

Takeda Pharmaceutical (TAK) is larger, with a market capitalization of $69.55B compared with $31.01B for Insmed (INSM).

Which stock has performed better over the past year, INSM or TAK?

TAK returned +52.24% over the past 12 months, compared with -28.89% for INSM (price return, excluding dividends). Past performance does not predict future results.

Which pays a higher dividend, Insmed or Takeda Pharmaceutical?

Takeda Pharmaceutical pays a dividend yielding 927.88%, while Insmed does not currently pay a regular dividend.

Are Insmed and Takeda Pharmaceutical in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons